| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
6.49(B) |
| Last
Volume: |
1,548,181 |
Avg
Vol: |
2,440,013 |
| 52
Week Range: |
$18.78 - $24.13 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 14.9 |
| Insider 6 Months : 16.6 |
| Insider 3/6 Months : 32 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
190,000 |
310,409 |
310,409 |
310,409 |
| Total Buy Value |
$3,932,734 |
$6,534,772 |
$6,534,772 |
$6,534,772 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
77,148 |
336,706 |
542,969 |
981,371 |
| Total Sell Value |
$1,703,116 |
$7,468,007 |
$11,664,525 |
$19,365,156 |
| Total People Sold |
3 |
5 |
6 |
10 |
| Total Sell Transactions |
3 |
9 |
13 |
25 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Senner Christopher J. |
EVP and CFO |
• – – |
2020-11-15 |
4 |
D |
$20.16 |
$274,116 |
D/D |
(13,597) |
245,596 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2020-11-15 |
4 |
D |
$20.16 |
$228,030 |
D/D |
(11,311) |
283,124 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-11-15 |
4 |
D |
$20.16 |
$503,073 |
D/D |
(24,954) |
573,880 |
|
- |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2020-11-15 |
4 |
OE |
$7.27 |
$218,100 |
D/D |
30,000 |
494,254 |
|
- |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2020-11-15 |
4 |
D |
$20.16 |
$206,862 |
D/D |
(10,261) |
464,254 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2020-11-15 |
4 |
D |
$20.16 |
$301,452 |
D/D |
(14,953) |
477,399 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2020-11-10 |
4 |
S |
$20.61 |
$700,740 |
D/D |
(34,000) |
197,809 |
|
-7% |
|
| Wyszomierski Jack L |
Director |
– • – |
2020-11-10 |
4 |
OE |
$5.82 |
$363,185 |
D/D |
62,403 |
231,809 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2020-10-22 |
4 |
D |
$21.79 |
$1,203,571 |
D/D |
(55,235) |
491,835 |
|
- |
|
| Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
• – – |
2020-10-22 |
4 |
A |
$0.00 |
$0 |
D/D |
213,879 |
547,070 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2020-10-22 |
4 |
D |
$21.79 |
$962,769 |
D/D |
(44,184) |
249,618 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2020-10-22 |
4 |
A |
$0.00 |
$0 |
D/D |
178,231 |
293,802 |
|
- |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2020-10-22 |
4 |
D |
$21.79 |
$1,018,508 |
D/D |
(46,742) |
474,515 |
|
- |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2020-10-22 |
4 |
A |
$0.00 |
$0 |
D/D |
178,231 |
521,257 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-10-22 |
4 |
D |
$21.79 |
$3,859,706 |
D/D |
(177,132) |
598,834 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2020-10-22 |
4 |
A |
$0.00 |
$0 |
D/D |
672,861 |
775,966 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2020-10-22 |
4 |
D |
$21.79 |
$1,022,387 |
D/D |
(46,920) |
259,193 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2020-10-22 |
4 |
A |
$0.00 |
$0 |
D/D |
178,231 |
306,113 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2020-10-22 |
4 |
D |
$21.79 |
$1,155,349 |
D/D |
(53,022) |
294,435 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2020-10-22 |
4 |
A |
$0.00 |
$0 |
D/D |
213,879 |
347,457 |
|
- |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2020-10-21 |
4 |
AS |
$21.95 |
$872,337 |
D/D |
(39,742) |
343,026 |
|
-2% |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2020-10-21 |
4 |
OE |
$7.27 |
$288,924 |
D/D |
39,742 |
382,768 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2020-10-08 |
4 |
AS |
$25.00 |
$250,000 |
D/D |
(10,000) |
127,882 |
|
-10% |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2020-10-08 |
4 |
OE |
$3.66 |
$36,600 |
D/D |
10,000 |
137,882 |
|
- |
|
| Hessekiel Jeffrey |
EVP and General Counsel |
• – – |
2020-09-22 |
4 |
AS |
$26.14 |
$268,144 |
D/D |
(10,258) |
343,026 |
|
-11% |
|
985 Records found
|
|
Page 14 of 40 |
|
|
0.32 (1.51%) 
